Bu öğeden alıntı yapmak, öğeye bağlanmak için bu tanımlayıcıyı kullanınız:
http://hdl.handle.net/11452/23190
Tüm üstveri kaydı
Dublin Core Alanı | Değer | Dil |
---|---|---|
dc.date.accessioned | 2021-12-13T07:19:03Z | - |
dc.date.available | 2021-12-13T07:19:03Z | - |
dc.date.issued | 2009-06 | - |
dc.identifier.citation | Nak, D. vd. (2009). "Follow-up examinations after medical treatment of pyometra in cats with the progesterone-antagonist aglepristone". Journal of Feline Medicine and Surgery, 11(6), 499-502. | en_US |
dc.identifier.issn | 1098-612X | - |
dc.identifier.uri | https://doi.org/10.1016/j.jfms.2008.09.006 | - |
dc.identifier.uri | https://journals.sagepub.com/doi/10.1016/j.jfms.2008.09.006 | - |
dc.identifier.uri | http://hdl.handle.net/11452/23190 | - |
dc.description.abstract | The aim of this study was to determine the therapeutic Success Of the medical treatment of pyometra with the antigestagen aglepristone and to document the recurrence rate in relation to the time interval after treatment with antigestagens in cats. Ten cats, 2-13 years of age and nulliparous were used in the Study. The cats were treated with aglepristone at a dose of 10 mg/kg body weight subcutaneously on days 1, 2, 7 and 14 (if not cured). In addition, trimethoprim/sulphadoxine was also administered at a dose of 15 mg/kg body weight subcutaneously once a day for 7 days. Nine out of the 10 cats responded well to treatment. No recurrence was observed in a follow-up period of 2 years. No side effects were observed. The data suggest that aglepristone treatment is a promising approach for the medical treatment of pyometra in cats. | en_US |
dc.language.iso | en | en_US |
dc.publisher | Sage Publications | en_US |
dc.rights | info:eu-repo/semantics/closedAccess | en_US |
dc.subject | Reproduction | en_US |
dc.subject | Hyperplasia | en_US |
dc.subject | Veterinary sciences | en_US |
dc.subject.mesh | Animals | en_US |
dc.subject.mesh | Anti-bacterial agents | en_US |
dc.subject.mesh | Cat diseases | en_US |
dc.subject.mesh | Cats | en_US |
dc.subject.mesh | Drug therapy, combination | en_US |
dc.subject.mesh | Estrenes | en_US |
dc.subject.mesh | Female | en_US |
dc.subject.mesh | Injections, subcutaneous | en_US |
dc.subject.mesh | Male | en_US |
dc.subject.mesh | Progestins | en_US |
dc.subject.mesh | Pyometra | en_US |
dc.subject.mesh | Sulfadoxine | en_US |
dc.subject.mesh | Treatment outcome | en_US |
dc.subject.mesh | Trimethoprim | en_US |
dc.title | Follow-up examinations after medical treatment of pyometra in cats with the progesterone-antagonist aglepristone | en_US |
dc.type | Article | en_US |
dc.identifier.wos | 000267109400014 | tr_TR |
dc.identifier.scopus | 2-s2.0-67349148579 | tr_TR |
dc.relation.publicationcategory | Makale - Uluslararası Hakemli Dergi | tr_TR |
dc.contributor.department | Uludağ Üniversitesi/Tıp Fakültesi/Kadın Hastalıkları ve Doğum Anabilim Dalı. | tr_TR |
dc.contributor.department | Uludağ Üniversitesi/Veterinerlik Fakültesi. | tr_TR |
dc.identifier.startpage | 499 | tr_TR |
dc.identifier.endpage | 502 | tr_TR |
dc.identifier.volume | 11 | tr_TR |
dc.identifier.issue | 6 | tr_TR |
dc.relation.journal | Journal of Feline Medicine and Surgery | en_US |
dc.contributor.buuauthor | Nak, Deniz | - |
dc.contributor.buuauthor | Nak, Yavuz | - |
dc.contributor.buuauthor | Tuna, Bilginer | - |
dc.contributor.researcherid | AAH-5494-2021 | tr_TR |
dc.identifier.pubmed | 19097817 | tr_TR |
dc.subject.wos | Veterinary sciences | en_US |
dc.indexed.wos | SCIE | en_US |
dc.indexed.scopus | Scopus | en_US |
dc.indexed.pubmed | Pubmed | en_US |
dc.wos.quartile | Q2 | en_US |
dc.contributor.scopusid | 9280090000 | tr_TR |
dc.contributor.scopusid | 8615464000 | tr_TR |
dc.contributor.scopusid | 9280090300 | tr_TR |
dc.subject.scopus | Pyometra; Bitches; Deslorelin | en_US |
dc.subject.emtree | Aglepristone | en_US |
dc.subject.emtree | Antiinfective agent | en_US |
dc.subject.emtree | Estrane derivative | en_US |
dc.subject.emtree | Gestagen | en_US |
dc.subject.emtree | Sulfadoxine | en_US |
dc.subject.emtree | Trimethoprim | en_US |
dc.subject.emtree | Animal | en_US |
dc.subject.emtree | Animal disease | en_US |
dc.subject.emtree | Article | en_US |
dc.subject.emtree | Cat | en_US |
dc.subject.emtree | Cat disease | en_US |
dc.subject.emtree | Drug antagonism | en_US |
dc.subject.emtree | Drug combination | en_US |
dc.subject.emtree | Female | en_US |
dc.subject.emtree | Male | en_US |
dc.subject.emtree | Pyometra | en_US |
dc.subject.emtree | Subcutaneous drug administration | en_US |
dc.subject.emtree | Treatment outcome | en_US |
Koleksiyonlarda Görünür: | Scopus Web of Science |
Bu öğenin dosyaları:
Bu öğeyle ilişkili dosya bulunmamaktadır.
DSpace'deki bütün öğeler, aksi belirtilmedikçe, tüm hakları saklı tutulmak şartıyla telif hakkı ile korunmaktadır.